Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial
Paul Hartley, Yue Shentu, Patricia Betz-Schiff et al. · Drugs & Aging · 2015
Cited by 31 works. doi:10.1007/s40266-015-0271-z
Authors
- Paul Hartley
- Yue Shentu
- Patricia Betz-Schiff
- Gregory T. Golm
- Christine McCrary Sisk
- Samuel S. Engel
- R. Ravi Shankar
References
- Global Prevalence of Diabetes
- Comparative analysis of two rates
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial
- Hypoglycaemia in Type 2 diabetes
- The Burden and Treatment of Diabetes in Elderly Individuals in the U.S.
- Hypoglycemia Unawareness in Older Compared With Middle-Aged Patients With Type 2 Diabetes
- Counterregulatory Hormone Responses to Hypoglycemia in the Elderly Patient with Diabetes
- Altered Hierarchy of Protective Responses Against Severe Hypoglycemia in Normal Aging in Healthy Men
- Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin